Put companies on watchlist
PolyPeptide Group
ISIN: CH1110760852
WKN: A3CNHV
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

PolyPeptide Group · ISIN: CH1110760852 · EQS - adhoc news (39 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1211849
25 June 2021 07:00AM

PolyPeptide Group appoints Christina Del Vecchio as General Counsel and member of the Executive Committee


EQS Group-Ad-hoc: PolyPeptide Group / Key word(s): Personnel
PolyPeptide Group appoints Christina Del Vecchio as General Counsel and member of the Executive Committee

25-Jun-2021 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Media Release - ad hoc announcement pursuant to Art. 53 LR

PolyPeptide Group appoints Christina Del Vecchio as General Counsel and member of the Executive Committee

Zug, 25 June 2021 - PolyPeptide Group AG, a global leader in peptide development and manufacturing, today announced the appointment of Christina Del Vecchio as General Counsel and member of the Executive Committee. She will join PolyPeptide on 1 September 2021 and will also serve as the company's Corporate Secretary.

PolyPeptide CEO Raymond De Vré comments: "We are excited to welcome Christina who already has a deep knowledge and understanding of our company having worked closely with us on our recent IPO on SIX Swiss Exchange. With her extensive international legal and public company experience as well as her pragmatic and commercial mindset, Christina brings the ideal blend of capabilities for this newly created role, aimed at supporting our organization as we develop and grow our global business."

Christina Del Vecchio joins PolyPeptide from Niederer Kraft Frey AG, a leading Swiss law firm based in Zurich, where she has worked since 2013, becoming counsel in 2018. Prior to joining Niederer Kraft Frey AG, she was an associate at Latham & Watkins LLP in their London office. Over the course of her career, Christina has advised numerous Swiss and international companies on a wide range of commercial and financing transactions, securities laws, governance, compliance and other legal matters.

Christina graduated from Columbia Law School in 2008, where she was recognized as a James Kent Scholar, and summa cum laude from the University of Florida in 2000 with a Bachelor of Arts. Christina, who was born in 1978 and raised in the U.S., is a Swiss and Swedish citizen.

Contact
Michael Stäheli, Head of Investor Relations & Corporate Communications
michael.staeheli@polypeptide.com, +41 41 723 20 34

About PolyPeptide Group
PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products. Dating back to 1952, PolyPeptide today manufactures around one-half of all currently approved peptide drug substances with a global footprint of six GMP-certified facilities in Europe, the U.S. and India. As a multinational company with more than 900 employees, its diversity brings breadth, depth of knowledge and experience to the group. PolyPeptide has grown organically and by selective acquisition of existing expertise, culminating in its position today as a leader in outsourced peptide manufacturing. PolyPeptide's shares (SIX: PPGN) are listed on the Swiss Stock Exchange. For more information, visit polypeptide.com.

Disclaimer
This release contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.


Additional features:


File: PolyPeptide_General_Counsel_EN

End of ad hoc announcement
Language: English
Company: PolyPeptide Group
Dammstrasse 19
CH-6300 Zug
Switzerland
Phone: +41 41 723 23 23
E-mail: mediateam@polypeptide.com
Internet: www.polypeptide.com
ISIN: CH1110760852
Valor: 111076085
Listed: SIX Swiss Exchange
EQS News ID: 1211849

 
End of Announcement EQS Group News Service

1211849  25-Jun-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1211849&application_name=news&site_id=boersengefluester_html
Visual performance / price development - PolyPeptide Group
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.